• Jason Fangusaro, Olaf Witt, Hernáiz Driever Pablo P Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, Ber, Asim K Bag, Peter de Blank, Nadja Kadom, Lindsay Kilburn, Robert M Lober, Nathan J Robison, Michael J Fisher, Roger J Packer, Young Poussaint Tina T Department of Radiology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA., Ludmila Papusha, Shivaram Avula, Alba A Brandes, Eric Bouffet, Daniel Bowers, Anton Artemov, Murali Chintagumpala, David Zurakowski, Martin van den Bent, Brigitte Bison, Kristen W Yeom, Walter Taal, and Katherine E Warren.
• Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, Aflac Cancer Center, Emory University and the Children's Healthcare of Atlanta, Atlanta, GA, USA. Electronic address: jfangus@emory.edu.
• Lancet Oncol. 2020 Jun 1; 21 (6): e305-e316.

AbstractPaediatric low-grade gliomas (also known as pLGG) are the most common type of CNS tumours in children. In general, paediatric low-grade gliomas show clinical and biological features that are distinct from adult low-grade gliomas, and the developing paediatric brain is more susceptible to toxic late effects of the tumour and its treatment. Therefore, response assessment in children requires additional considerations compared with the adult Response Assessment in Neuro-Oncology criteria. There are no standardised response criteria in paediatric clinical trials, which makes it more difficult to compare responses across studies. The Response Assessment in Pediatric Neuro-Oncology working group, consisting of an international panel of paediatric and adult neuro-oncologists, clinicians, radiologists, radiation oncologists, and neurosurgeons, was established to address issues and unique challenges in assessing response in children with CNS tumours. We established a subcommittee to develop consensus recommendations for response assessment in paediatric low-grade gliomas. Final recommendations were based on literature review, current practice, and expert opinion of working group members. Consensus recommendations include imaging response assessments, with additional guidelines for visual functional outcomes in patients with optic pathway tumours. As with previous consensus recommendations, these recommendations will need to be validated in prospective clinical trials.Copyright © 2020 Elsevier Ltd. All rights reserved.

30 keywords...

hide…